Regular ArticleOnset of Action of Single Doses of Formoterol Administered via Turbuhaler in Patients with Stable COPD☆
References (19)
- et al.
The use of bronchodilators in stable chronic obstructive pulmonary disease
Pulm Pharmacol Ther
(1997) - et al.
Should long-acting beta2-agonists be considered an alternative first choice option for the treatment of stable COPD ?
Respir Med
(1999) Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta2-adrenoceptor agonist bronchodilator
Life Sci
(1993)- et al.
Rapid onset of action of inhaled formoterol in asthmatic patients
Chest
(1992) - et al.
Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease
Pulm Pharmacol
(1994) - et al.
Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study
Respir Med
(1995) - et al.
Management of chronic obstructive pulmonary disease
N Engl J Med
(1993) - et al.
Effects of a pre-treatment with conventional doses of formoterol, salmeterol or oxitropium bromide on the dose-response curves to salbutamol in patients suffering from partially reversible COPD
Eur Respir J
(1998) - et al.
Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma
Thorax
(1993)
Cited by (36)
Pharmacological treatment of stable chronic obstructive pulmonary disease
2009, Presse MedicaleFaster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: A multicenter, randomized study
2009, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :In that study of 47 patients aged 42–80 years, the absolute change from baseline (P = 0.0044) and percentage change from baseline line in FEV1 (P = 0.0021) for patients taking formoterol 12 μg were found to be superior to changes in FEV1 for patients taking salmeterol 50 μg [16]. An additional small study (n = 22) also reported a faster onset of action when formoterol was compared with salmeterol [21], and similar onset of action was observed when compared with salbutamol (albuterol) [25]. Similar studies have also documented an onset of action of less than 5 min when formoterol was compared with ipratropium in patients with COPD [6].
Efficacy of formoterol Turbuhaler in the emergency treatment of patients with obstructive airway diseases
2008, Respiratory MedicineCitation Excerpt :Nevertheless, patients with stable COPD and patients with an acute and severe asthma exacerbation were able to generate a peak inspiratory flow (PIF) through the Turbuhaler, which would theoretically allow an efficient disintegration of drug particles from this device during inhalation.6,7 Formoterol is a β-2 agonist with a rapid onset of action, comparable to that of the traditional short-acting bronchodilators8,9 but it also has a long duration of effect.10 Recent studies showed the inhaled formoterol Turbuhaler to be more effective than both terbutaline and salbutamol when used “as needed” in both asthma and COPD.11–14
Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease
2008, Respiratory MedicineCitation Excerpt :Time to maximum increase in FEV1 with albuterol, formoterol, and salmeterol was 1, 4, and 5 h, respectively. These results differ markedly from results reported later by this same group 16,17 and by Benhamou and colleagues.18 Two crossover studies demonstrated that formoterol has a faster onset of effect than the short-acting anticholinergic bronchodilator, ipratropium.
- ☆
Author for correspondence: Mario Cazzola, Via del Parco Margherita 24, 80121 Napoli, Italy. Fax: +39 081 7473331. E-mail: Í[email protected]